Sickness Evaluation at Altitude With Acetazolamide at Relative Doses
Status:
Completed
Trial end date:
2019-09-29
Target enrollment:
Participant gender:
Summary
The specific aim of this study is to evaluate whether acetazolamide 125mg daily is no worse
than acetazolamide 250mg daily in decreasing the incidence of acute mountain sickness (AMS)
in travelers to high altitude. The study population is hikers who are ascending at their own
rate under their own power in a true hiking environment at the White Mountain Research
Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain,
California